147 related articles for article (PubMed ID: 26045017)
1. RUNX3 Modulates Metastatic Potential in Pancreatic Ductal Adenocarcinoma.
Cancer Discov; 2015 Jul; 5(7):OF27. PubMed ID: 26045017
[TBL] [Abstract][Full Text] [Related]
2. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
Whittle MC; Izeradjene K; Rani PG; Feng L; Carlson MA; DelGiorno KE; Wood LD; Goggins M; Hruban RH; Chang AE; Calses P; Thorsen SM; Hingorani SR
Cell; 2015 Jun; 161(6):1345-60. PubMed ID: 26004068
[TBL] [Abstract][Full Text] [Related]
3. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
4. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
Jian Z; Cheng T; Zhang Z; Raulefs S; Shi K; Steiger K; Maeritz N; Kleigrewe K; Hofmann T; Benitz S; Bruns P; Lamp D; Jastroch M; Akkan J; Jäger C; Huang P; Nie S; Shen S; Zou X; Ceyhan GO; Michalski CW; Friess H; Kleeff J; Kong B
Cell Mol Gastroenterol Hepatol; 2018; 6(4):429-449. PubMed ID: 30258965
[TBL] [Abstract][Full Text] [Related]
5. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.
Dai C; Rennhack JP; Arnoff TE; Thaker M; Younger ST; Doench JG; Huang AY; Yang A; Aguirre AJ; Wang B; Mun E; O'Connell JT; Huang Y; Labella K; Talamas JA; Li J; Ilic N; Hwang J; Hong AL; Giacomelli AO; Gjoerup O; Root DE; Hahn WC
Cell Rep; 2021 Jul; 36(4):109443. PubMed ID: 34320363
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas.
Furukawa T
J Hepatobiliary Pancreat Surg; 2007; 14(3):233-7. PubMed ID: 17520197
[TBL] [Abstract][Full Text] [Related]
7. Expression of RUNX3 gene in pancreatic adenocarcinoma and its clinical significance.
Xue LN; Bai FH; Wang XY; Lin M; Tan Y; Yao XY; Xu KQ
Genet Mol Res; 2014 May; 13(2):3940-6. PubMed ID: 24938604
[TBL] [Abstract][Full Text] [Related]
8. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
10. The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors?
Funel N
Epigenomics; 2015; 7(3):333-5. PubMed ID: 26077422
[No Abstract] [Full Text] [Related]
11. Runx3 and Cell Fate Decisions in Pancreas Cancer.
Whittle MC; Hingorani SR
Adv Exp Med Biol; 2017; 962():333-352. PubMed ID: 28299667
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
[TBL] [Abstract][Full Text] [Related]
13. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Sunamura M; Lefter LP; Duda DG; Morita R; Inoue H; Yokoyama T; Yatsuoka T; Abe T; Egawa S; Furukawa T; Fukushige S; Oshimura M; Horii A; Matsuno S
Pancreas; 2004 Apr; 28(3):311-6. PubMed ID: 15084978
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
15. Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression.
Xu H; Inagaki Y; Seyama Y; Hasegawa K; Sugawara Y; Du G; Wang F; Tang W; Kokudo N
Life Sci; 2011 Jun; 88(23-24):1063-9. PubMed ID: 21466814
[TBL] [Abstract][Full Text] [Related]
16. [Pathologic characteristics and evaluation of the pancreatic cancer].
Fukushima N; Mukai K
Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
[TBL] [Abstract][Full Text] [Related]
17. Where and when does pancreatic carcinoma start?
Lüttges J; Hahn S; Klöppel G
Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma.
Ono M; Nakamura T; Mizukami Y; Hirano S
Ann Surg Oncol; 2022 Aug; 29(8):5020-5021. PubMed ID: 35527329
[No Abstract] [Full Text] [Related]
19. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
20. GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability.
Schneider G; Weber A; Zechner U; Oswald F; Friess HM; Schmid RM; Liptay S
Int J Cancer; 2006 May; 118(10):2405-11. PubMed ID: 16353139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
